Systemischer Lupus Erythematodes 2023

Zusammenfassung

Mit zwei neuen Zulassungen in den letzten Jahren, einem Update der EULAR Empfehlungen zum Management des systemischer Lupus erythematodes (SLE) 2023 und neuen, vielversprechenden Therapieoptionen konnten in der SLE-Therapie bedeutende Fortschritte erzielt werden. Nach wie vor steht der individuelle Patient im Fokus, und Therapieansätze richten sich nach Manifestationen und Patientencharakteristika. Durch das erweitere Armamentarium stehen nun jedoch mehr Optionen zu Verfügung.

Abstract

With two new approvals in recent years, an update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE) in 2023, and promising new therapeutic options, significant progress has been made in the treatment of SLE. The individual patient continues to be the focus, and therapeutic approaches are based on manifestations and patient characteristics. Owing to the expanded armamentarium, however, more options are now available.

Schlüsselwörter

systemischer Lupus erythematodes - Antikörpertherapie - Therapieempfehlungen

Keywords

systemic lupus erythematosus - antibody treatment - treatment recommendationsArtikel online veröffentlicht 2024

Publikationsverlauf

Artikel online veröffentlicht:
07. Mai 2024

• Literatur

• 1 Mougiakakos D, Krönke G, Völkl S. et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med 2021; 385: 567-569 DOI: 10.1056/NEJMc2107725.
• 2 Fanouriakis A, Kostopoulou M, Andersen J. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2023; DOI: 10.1136/ard-2023-224762.
• 3 Mackensen A, Müller F, Mougiakakos D. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022; 28: 2124-2132 DOI: 10.1038/s41591-022-02017-5.
• 4 Aringer M, Finzel S, Voll RE. Immunpathogenese des systemischen Lupus erythematodes. Z Rheumatol 2022; DOI: 10.1007/s00393-022-01214-4.
• 5 Furie RA, Aroca G, Cascino MD. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2021; DOI: 10.1136/annrheumdis-2021-220920.
• 6 Rovin BH, Furie RA, Ross Terres JA. et al. Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial. Arthritis & rheumatology (Hoboken, N.J.) 2023; DOI: 10.1002/art.42734.
• 7 Di Wu LiJ, Xu D. et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2023; DOI: 10.1136/ard-2023-224854.
• 8 Ostendorf L, Burns M, Durek P. et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med 2020; 383: 1149-1155 DOI: 10.1056/NEJMoa2023325.
• 9 Morand EF, Furie R, Tanaka Y. et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 2020; 382: 211-221 DOI: 10.1056/NEJMoa1912196.
• 10 Furie R, Morand EF, Askanase AD. et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 2021; 30: 1254-1263 DOI: 10.1177/09612033211014267.
• 11 Furie R, Khamashta M, Merrill JT. et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis &. rheumatology (Hoboken, N.J.) 2017; 69: 376-386 DOI: 10.1002/art.39962.
• 12 Kalunian KC, Furie R, Morand EF. et al. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2023; 75: 253-265 DOI: 10.1002/art.42392.
• 13 Jayne D, Rovin B, Mysler E. et al. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Sci Med 2023; 10 DOI: 10.1136/lupus-2023-000910.
• 14 Rovin BH, Teng YKO, Ginzler EM. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2070-2080 DOI: 10.1016/S0140-6736(21)00578-X.
• 15 Rovin BH, Furie R, Teng YKO. et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 2022; 101: 403-413 DOI: 10.1016/j.kint.2021.08.027.
• 16 Isenberg D, Appel GB, Contreras G. et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49: 128-140 DOI: 10.1093/rheumatology/kep346.
• 17 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M. et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 2017; 76: 1575-1582 DOI: 10.1136/annrheumdis-2016-210882.
• 18 Almeida-Brasil CC, Hanly JG, Urowitz M. et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 2022; 81: 370-378 DOI: 10.1136/annrheumdis-2021-221295.
• 19 Kidney Disease: Improving Global Outcomes. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int 2024; 105: S1-S69 DOI: 10.1016/j.kint.2023.09.002.
• 20 Khairani CD, Bejjani A, Piazza G. et al. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. J Am Coll Cardiol 2023; 81: 16-30 DOI: 10.1016/j.jacc.2022.10.008.
• 21 Yang Z, Cheng C, Wang Z. et al. Prevalence, Predictors, and Prognostic Benefits of Remission Achievement in Patients With Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res (Hoboken) 2022; 74: 208-218 DOI: 10.1002/acr.24464.